Recent evidence suggests that pharmacological inhibition of ANO1 may have beneficial effects on HNSCC, esophageal squamous cell carcinoma (ESCC), gastrointestinal stromal tumours (GIST), breast and prostate cancer [5, 15, 16]. Here, ANO1 is linked to prostate cancer.